Gastric Cancer Surgery Success Rates in Intermediate and Advanced Stages

At present, the safety of surgical procedures for intermediate and advanced stage gastric cancer is relatively well assured. With comprehensive treatment approaches, the 5-year survival rate ranges between 50% and 60%. However, this outcome largely depends on several key factors such as the depth of tumor invasion, whether lymph node metastasis is present, if a radical resection was performed during surgery, and whether follow-up comprehensive treatment was carried out after the operation.

Comprehensive treatment during the perioperative period is currently the standard approach for managing intermediate and advanced gastric cancer. This includes preoperative neoadjuvant chemotherapy, postoperative adjuvant chemotherapy, and may also incorporate immunotherapy, targeted therapy, hyperthermia, and radiotherapy. These modalities work together to improve the overall prognosis.

The 5-year survival rate has significantly improved compared to 10 or 20 years ago, largely due to advancements in comprehensive treatment strategies. The development of targeted therapies and immunotherapies has played a crucial role in this progress. Combining the latest drug treatments with surgical interventions has led to better outcomes for patients with intermediate and advanced gastric cancer.

These treatment improvements have transformed the landscape of gastric cancer management, offering hope for longer survival and better quality of life. As medical science continues to evolve, new therapies and combinations are being tested to further enhance survival rates and reduce recurrence risks.